Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI France ETF (EWQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI France ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while iShares MSCI France ETF trades at $47.54. The key difference: iShares MSCI France ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | EWQ | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $48.35 |
52-Week Low | $0.48 | $41.68 |
Enterprise Value | $16.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
EWQ, the iShares MSCI France ETF, trades at $47.54, down 0.44% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is concentrated in industrials and benefits from positive momentum in European equities, with a dividend scheduled for June 2026. Recent news highlights France's tech investments and ECB rate decisions influencing regional economic sentiment.
The outlook for EWQ is supported by favorable European market trends and institutional interest, though risks include geopolitical tensions affecting energy prices and potential ECB tightening. Investors should weigh the ETF's exposure to French equities against macroeconomic headwinds for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →
